Lpl variant therapeutics
CA 2370081 C · Owner: Academic Hospital At The University Of Amsterdam · Inventors: Kastelein, John J. P.; Hayden, Michael R.; Excoffon, Katherine Julie Diane Ashbourne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (LPL S447X) including nucleic acids encoding such proteins, for the treatment of conditions including LPL responsive conditions such as cardiovascular disease, hypertension LPL deficiency, high , triglyceride levels low HDL-cholesterol levels or atherosclerosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 23, 2000 and granted June 3, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 23, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 23, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.